Gadolinium Neutron Capture Therapy (GdNCT) with MRI Contrast Media. In Vitro Studies
Boron Neutron Capture Therapy (BNCT) is considered a promising therapy for the treatment of malignant brain tumors and malignant melanomas. Two boron compounds, the mercaptoundecahydro-closo-dodecaborate dianion ([B12H11,SH]2-, BSH) and boronophenylalanine (4-(dihydroxyboryl)phenylalanine, BPA), have entered the clinical research stage. (In both cases intracellular uptake by the target cells has been discussed.) For the evaluation of their pharmacokinetics and organ distribution, rather involved experimental techniques far from routine diagnostics are currently being used in treatment planning1, e.g. 18F-substitution in combination with PET or 11B MRI.
KeywordsToxicity Quartz Lymphoma Boron Expense
Unable to display preview. Download preview PDF.
- 1.see this volume, e.g. contributions by: Y. Mishima; Y. Nakagawa & H. Hatanaka; H. Fukuda; K.M. Bradshaw et al.Google Scholar
- 2.G. Wolf, K.R. Burnett, E.J. Goldstein, and P.M. Joseph, Contrast agents for magnetic resonance imaging, in “Magnetic Resonance Annual’’, H.Y. Kressel, ed., Raven Press, New York, 1985, pp. 231–266.Google Scholar
- 12.Y. Akine, N. Tokita, K. Tokuuye, M. Satoh, T. Kobayashi, K. Kanda, Electron-equivalent dose for the effect of Gadolinium neutron capture therapy on the growth of subcutaneously-inoculated Ehrlich tumor cells in mice. Jpn. J. Clin. Oncol. 23: N3, 145–148, 1993.Google Scholar